WASHINGTON DC—A new blood test has detected drug-resistant mutations reliably in patients with gastrointestinal stromal tumour (GIST) helping to guide therapy when first-line drugs had failed. This was in a study using the recently approved agent regorafenib. Dr George Demetri of the Dana-Farber Harvard Cancer Center presented findings from the GRID study during the 2013 conference of the American Society for Cancer Research. He told Peter Goodwin why the blood test did better than biopsy testing and about the prospects of treating refractory GIST with rogarafenib.
You may also like...
Advanced, unresectable melanoma: survival rates at five years doubled with ipilimumab therapy 26 Oct, 2013 Audio Journal of Oncology in Advance – March 1st, 2008 4 Mar, 2008 Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 PDL1 inhibitor brings better responses in smokers with refractory lung cancer 19 Nov, 2013
- Previous story Gene expression and molecular pathways guide head and neck cancer therapies
- Next story Treatment “holidays” to overcome resistance in advanced melanoma?
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014